Dr. Fuchs on Angiogenesis in Gastric Cancer

Charles S. Fuchs, MD
Published: Thursday, Feb 20, 2014

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

In the AVAGAST trial, patients were randomized to chemotherapy or chemotherapy plus bevacizumab in the frontline. Results from the trial indicated a benefit to progression-free survival (PFS) and response, but no significant effect on overall survival (OS).

Fuchs says he was involved in a randomized study of ramucirumab, a monoclonal antibody against VEGFR2, compared with placebo in the second-line. Treatment with ramucirumab demonstrated significant improvement to OS and PFS, as well as a trivial toxicity profile.
 
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

In the AVAGAST trial, patients were randomized to chemotherapy or chemotherapy plus bevacizumab in the frontline. Results from the trial indicated a benefit to progression-free survival (PFS) and response, but no significant effect on overall survival (OS).

Fuchs says he was involved in a randomized study of ramucirumab, a monoclonal antibody against VEGFR2, compared with placebo in the second-line. Treatment with ramucirumab demonstrated significant improvement to OS and PFS, as well as a trivial toxicity profile.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x